Spero reports Q2 loss $11.9M; FDA SPA for tebipenem HBr P3 trial

Spero Therapeutics, Inc.

2023-Q2 EPS reported -$0.48 revenue$4,786,000

Net loss $11.9M ($0.23/sh) vs $28.7M ($0.87) in Q2 2022; revenue $2.7M.
FDA SPA agreement on design of Phase 3 PIVOT-PO trial for tebipenem HBr; first patient expected Q4 2023.
Sath Shukla appointed President and CEO effective Aug 1; succeeds Ankit Mahadevia (now Chairman).
Cash $77.7M + $30M GSK milestone; cash runway into H2 2025.
SPR720 Phase 2 trial enrolling, topline data H2 2024; SPR206 IND planned Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Spero Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $2.7 million, net income net loss of $11.9 million, EPS $0.23 per basic and diluted share.

Period: second quarter ended June 30, 2023
Revenue: $2.7 million
Net income: net loss of $11.9 million
EPS: $0.23 per basic and diluted share
Result: reported results

Exact text from the filing

Spero reported a net loss for the second quarter ended June 30, 2023 of $11.9 million or $0.23 per basic and diluted share of common stock, compared to a net loss of $28.7 million or $0.87 per basic and diluted share of common stock reported for the same period in 2022. Total revenues for the second quarter of 2023 were $2.7 million

View on SEC.gov

Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.